Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The BCL11A erythroid-specific enhancer is a non-coding regulatory DNA element located in intron 2 of the human BCL11A gene. It functions as a developmentally and lineage-specific enhancer, regulating BCL11A expression exclusively in erythroid (red blood cell) lineage cells. By controlling the transcription of BCL11A in erythroid cells, the enhancer is a key determinant of the fetal-to-adult hemoglobin switch, as BCL11A protein represses fetal (gamma-globin) hemoglobin expression. Disruption of this enhancer via genome editing in hematopoietic stem cells has emerged as a highly promising therapeutic strategy to induce fetal hemoglobin and treat disorders such as sickle cell disease and beta-thalassemia. Editing the enhancer enables selective reduction of BCL11A in erythroid cells, sparing its critical functions in other tissues, such as B-lymphocyte development. This approach preserves hematopoietic stem cell self-renewal and function, addressing safety concerns associated with complete BCL11A knockout. The first FDA-approved CRISPR/Cas9 gene therapy, exagamglogene autotemcel (Casgevy), targets this enhancer to treat sickle cell disease and transfusion-dependent beta-thalassemia.
CRISPR-Cas9-mediated disruption of the erythroid-specific enhancer of BCL11A, which reduces BCL11A expression in erythroid cells and reactivates fetal hemoglobin (HbF) production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL11A erythroid-specific enhancer.